Sagimet Biosciences Inc.(SGMT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

SGMT Sagimet Biosciences Inc.

Trading 05-04 12:43:22 EDT

7.63

+0.02

+0.26%

High7.99	Low7.47	Vol362.71K
Open7.77	D1 Closing7.61	Amplitude6.83%
Mkt Cap470.68M	Tradable Cap172.64M	Total Shares61.69M
T/O2.81M	T/O Rate1.60%	Tradable Shares22.63M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"SGMT","market":"US","secType":"STK","nameCN":"Sagimet Biosciences Inc.","latestPrice":7.63,"timestamp":1777912988131,"preClose":7.61,"halted":0,"volume":362713,"delay":0,"changeRate":0.0026281208935610475,"floatShares":22626486,"shares":61688300,"eps":-1.58,"marketStatus":"Trading","change":0.02,"latestTime":"05-04 12:43:22 EDT","open":7.77,"high":7.99,"low":7.47,"amount":2814118.0234102,"amplitude":0.068331,"askPrice":7.64,"askSize":303,"bidPrice":7.63,"bidSize":260,"shortable":3,"etf":0,"ttmEps":-1.58,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1777924800000},"marketStatusCode":2,"adr":0,"listingDate":1689307200000,"exchange":"NASDAQ","adjPreClose":7.61,"preHourTrading":{"tag":"盘前","latestPrice":7.84,"preClose":7.61,"latestTime":"09:28 EDT","volume":11813,"amount":91940.3474652,"timestamp":1777901305016,"change":0.23,"changeRate":0.030223,"amplitude":0.042339},"postHourTrading":{"tag":"盘后","latestPrice":7.57,"preClose":7.61,"latestTime":"19:47 EDT","volume":10110,"amount":76554.9036,"timestamp":1777679247840,"change":-0.04,"changeRate":-0.005256,"amplitude":0.018357},"volumeRatio":0.062043,"impliedVol":1.0755,"impliedVolPercentile":0.2112},"requestUrl":"/m/hq/s/SGMT/wiki","defaultTab":"wiki","newsList":[{"id":"2632954652","title":"Sagimet Biosciences Is Maintained at Buy by Canaccord Genuity","url":"https://stock-news.laohu8.com/highlight/detail?id=2632954652","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632954652?lang=en_us&edition=fundamental","pubTime":"2026-05-04 23:35","pubTimestamp":1777908900,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SGMT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 04, 2026 11:35 ET (15:35 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SGMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632958150","title":"Sagimet Biosciences, Inc. Class A (SGMT) Receives a Buy from JonesTrading","url":"https://stock-news.laohu8.com/highlight/detail?id=2632958150","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632958150?lang=en_us&edition=fundamental","pubTime":"2026-05-04 19:56","pubTimestamp":1777895775,"startTime":"0","endTime":"0","summary":"In a report released today, Debanjana Chatterjee from JonesTrading assigned a Buy rating to Sagimet Biosciences, Inc. Class A, with a price target ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/sagimet-biosciences-inc-class-a-sgmt-receives-a-buy-from-jonestrading-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/sagimet-biosciences-inc-class-a-sgmt-receives-a-buy-from-jonestrading-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SGMT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632648484","title":"Oppenheimer Adjusts Price Target on Sagimet Biosciences to $33 From $28, Maintains Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2632648484","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632648484?lang=en_us&edition=fundamental","pubTime":"2026-05-01 22:37","pubTimestamp":1777646278,"startTime":"0","endTime":"0","summary":"Sagimet Biosciences (SGMT) has an average rating of buy and mean price target of $27, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major ba","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SGMT","OPY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631541450","title":"Sagimet Biosciences Is Maintained at Buy by Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2631541450","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631541450?lang=en_us&edition=fundamental","pubTime":"2026-04-30 00:28","pubTimestamp":1777480080,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SGMT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 29, 2026 12:28 ET (16:28 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SGMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631651208","title":"Sagimet Biosciences price target lowered to $25 from $27 at Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2631651208","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631651208?lang=en_us&edition=fundamental","pubTime":"2026-04-29 21:09","pubTimestamp":1777468152,"startTime":"0","endTime":"0","summary":"Guggenheim lowered the firm’s price target on Sagimet Biosciences (SGMT) to $25 from $27 and keeps a Buy rating on the shares. The firm is “enthusi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/sagimet-biosciences-price-target-lowered-to-25-from-27-at-guggenheim-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/sagimet-biosciences-price-target-lowered-to-25-from-27-at-guggenheim-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SGMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631587461","title":"3 Penny Stocks to Watch Now, 4/28/26","url":"https://stock-news.laohu8.com/highlight/detail?id=2631587461","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631587461?lang=en_us&edition=fundamental","pubTime":"2026-04-29 02:07","pubTimestamp":1777399620,"startTime":"0","endTime":"0","summary":"High-Trend International Group ($HTCO), Youxin Technology Limited ($YAAS), and Sagimet Biosciences ($SGMT) are the three penny stocks to watch on A...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/3-penny-stocks-to-watch-now-4-28-26?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/3-penny-stocks-to-watch-now-4-28-26?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["YAAS","SGMT","BK4139","BK4134"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631582664","title":"Sagimet Biosciences holds a conference call","url":"https://stock-news.laohu8.com/highlight/detail?id=2631582664","media":"TIPRANKS","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631582664?lang=en_us&edition=fundamental","pubTime":"2026-04-29 01:15","pubTimestamp":1777396516,"startTime":"0","endTime":"0","summary":"Conference call with Julie Harper who will provide details on the acne program to be held on April 30 at 2 pm hosted by Sagimet Biosciences (SGMT)....","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/sagimet-biosciences-holds-a-conference-call-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/sagimet-biosciences-holds-a-conference-call-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SGMT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630370717","title":"BRIEF-Sagimet Biosciences Offers 29.17 Million Shares Of Series A Common Stock - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2630370717","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630370717?lang=en_us&edition=fundamental","pubTime":"2026-04-28 18:33","pubTimestamp":1777372392,"startTime":"0","endTime":"0","summary":"BRIEF-Sagimet Biosciences Offers 29.17 Million Shares Of Series A Common Stock - SEC FilingApril 28  - SEC Filing:SAGIMET BIOSCIENCES INC - OFFERING 29.17 MILLION SHARES OF SERIES A COMMON STOCK - SEC FILINGSource text: [ID:n0001104659-26-049662]Further company coverage: SGMT.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260428:nFWN41B0EW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SGMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630377677","title":"Sagimet Biosciences Inc - Offering 29.17 Mln Shares of Series a Common Stock - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2630377677","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630377677?lang=en_us&edition=fundamental","pubTime":"2026-04-28 18:13","pubTimestamp":1777371212,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260428:nFWN41B0EW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SGMT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630336343","title":"NASD Most Active Issues","url":"https://stock-news.laohu8.com/highlight/detail?id=2630336343","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630336343?lang=en_us&edition=fundamental","pubTime":"2026-04-28 05:43","pubTimestamp":1777326180,"startTime":"0","endTime":"0","summary":"GrShr 2x Sh NVDA Daily       NVD    86,032,989      4.81    -0.42     -8.03. Direxion TSLA Bull 2X       TSLL    85,596,829     12.32     0.15      1.23. Leverage 2X Lg TSLA Dly     TSLG    70,827,573      6.07     0.07      1.17. Leverage 2X Lg BMNR Dly     BMNG    58,643,668      1.39    -0.08     -5.44. ProShares UltraPro QQQ      TQQQ    54,954,708     62.64     0.08      0.13. Advanced Micro Devices       AMD    50,381,910    334.63   -13.18     -3.79. Direxion PLTR Bear 1X       PLTD    43,573,521      7.55     0.00      0.00. American Airlines Group      AAL    42,375,758     11.68    -0.42     -3.47","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2756315318.SGD","HK0000819398.USD","LU0106261372.USD","LU2125909593.SGD","SG9999018857.SGD","LU0557290698.USD","LU0494093205.USD","LU0124676726.USD","LU1720051108.HKD","LU1935043023.USD","LU2244417387.USD","AMUU","LU0708995401.HKD","IE00BK4W5M84.HKD","LU2746668974.SGD","LU2065171311.SGD","LU1244550494.USD","QCOM","LU1066051498.USD","LU1496350171.SGD","LU2357305700.SGD","NVDO","BK4141","IE000YTNTUN2.SGD","LU0788109477.HKD","LU2750360641.GBP","SGXZ51526630.SGD","BK4588","LU2362541273.HKD","LU0957808578.USD","LU0203347892.USD","LU1145028129.USD","LU1429558221.USD","LU0210533765.USD","IE000W1ABFV2.USD","NVD3.UK","LU0069063385.USD","LU0532188223.SGD","BK4604","LU1267930573.SGD","LU2602419157.SGD","LU1934455277.USD","LU0823421416.USD","LU1202635105.USD","LU2322448791.USD","IE00BMPRXN33.USD","LU0640476718.USD","04335","LU0029864427.USD","LU0048584097.USD","NVDX","HK0000304805.HKD","LU1280957306.USD","QCML","LU0211327993.USD","LU0642271901.SGD","LU1153585028.USD","BK4099","TSII","LU0070217475.USD","TSLO","LU1244550221.USD","3NVD.UK","BK4587","LU0082616367.USD","IE00B19Z8X17.USD","LU0198837287.USD","LU0965509283.SGD","LU0889566641.SGD","DIPS","IE00BN29S564.USD","BK4553","NVDD","SG9999000418.SGD","INTW","SG9999002224.SGD","BK4602","IE0003U64NQ7.SGD","LU0310799852.SGD","LU2168564149.EUR","IE0004086264.USD","LU1951200564.SGD","LU0109391861.USD","HK0000306701.USD","SG9999018865.SGD","TSLI","SG9999015978.USD","BK4527","LU0943347566.SGD","LU1923623000.USD","TSL","LU2362540622.SGD","LU0079474960.USD","SG9999002620.SGD","IE0004091025.USD","LU1852331112.SGD","LU2462591277.SGD","LU2860962120.EUR","LU0345769128.USD","LU2100268510.USD","BK4532","LU1084165304.USD","LU2092937148.SGD","LU0708994859.HKD","LU2264538146.SGD","LU2047632596.USD","LU1645745479.HKD","IE00B3SWFQ91.USD","LU0210536198.USD","TSLG","LU0466842654.USD","SG9999014575.USD","LU0965508806.USD","IE00B3S45H60.SGD","SG9999002679.SGD","BK4555","IE00BQXX3F31.USD","BK4579","LU0274383776.USD","LU1839390173.USD","SG9999014898.SGD","LU1923622291.USD","LU1720051017.SGD","IE00BFSS8Q28.SGD","IE00BZ199S13.USD","LU2125154778.USD","LU0979878070.USD","LU0107464264.USD","LU0157215616.USD","LU1778281490.HKD","AMD","LU1861220033.SGD","BK4561","LU2271345857.HKD","LU2420271590.USD","IE0004445015.USD","IE00BJJMRX11.SGD","LU1629891620.HKD","LU2552382132.HKD","NVDL","LU1868836914.USD","LU0321505439.SGD","HK0000914660.USD","LU0128525929.USD","AMYY","NVD2.UK","LU0823434740.USD","AMDD","LU1861215975.USD","HK0000320223.HKD","LU1821325948.USD","IE0005OL40V9.USD","LU1242518931.SGD","LU0965509101.SGD","LU2023250504.SGD","LU1721428933.USD","DAMD","LU2463028550.USD","BK4614","IE00BD6J9T35.USD","LU0985320562.USD","TESL","HK0000320264.USD","LU0175139822.USD","LU2111349929.HKD","LU2750360997.AUD","ANV","BK4534","LU1303367103.USD","LU1868836757.USD","LU1935042488.USD","LU2505996509.AUD","BYND","LU2097344431.USD","LU2471134879.HKD","LU2290526834.HKD","BK4608","LU0210637038.USD","LU0174119429.USD","LU2272731600.USD","LU0689626769.HKD","LU1934455863.HKD","LU0965509010.AUD","LU2048586759.USD","LU0096362180.USD","QCMU","LU2211815571.USD","LU0348723411.USD","LU2125909759.SGD","LU0238689110.USD","LU2430703095.HKD","LU0081259029.USD","IE00BK4W5L77.USD","IE00BWXC8680.SGD","LU1323610961.USD","TSLT","LU3102509885.SGD","LU2265009873.SGD","LU0672654240.SGD","LU1116320901.HKD","BK4516","LU2381873111.SGD","IE00BVYPNP33.GBP","LU1127390331.HKD","NVDS.UK","LU1992135399.USD","LU0251132253.USD","LU0187121727.USD","LU0234570918.USD","LU0276348264.USD","SGXZ99366536.SGD","LU0354030438.USD","LU0211328371.USD","LU0823434583.USD","LU2360106780.USD","LU0882574139.USD","LU1400636657.SGD","IE00B19Z3B42.SGD",".IXIC","LU2473716301.USD","LU2106854487.HKD","AMDY","LU1366192091.USD","LU0345768740.USD","IE00B4YYXB79.USD","LU0133085943.USD","LU0158827948.USD","IE00BZ1G4Q59.USD","LU2360107168.USD","IE00B775H168.HKD","SG9999013460.SGD","IE00B3M56506.USD","BK4585","LU2361044949.HKD","LU1316542783.SGD","LU0080751232.USD","LU2362541513.USD","LU1069344957.HKD","LU0342679015.USD","LU0256863811.USD","LU1064131342.USD","LU0011850046.USD","BK4503","LU0345770308.USD","LU2403377893.USD","GRAB","IE00B775SV38.USD","LU0267386448.USD","LU1232071149.USD","LU2097344357.USD","LU2543165471.USD","LU2413666426.HKD","HK0000306685.HKD","LU0444973449.USD","LU0234572021.USD","LU2471134523.USD","LU2452424414.USD","NVII","LU2237438978.USD","IE00BKVL7J92.USD","LU2462157665.USD","LU1496350502.SGD","LU2417539215.USD","LU1861558580.USD","LU0353189680.USD","LU2023251221.USD","LU2087621335.USD","SGXZ23171101.USD","LU2077746001.SGD","SG9999017495.SGD","LU1917777945.USD","NVDQ","BK4573","IE00B4JS1V06.HKD","LU0308772762.SGD","LU2931357623.SGD","LU0417517546.SGD","LU1116320737.USD","LU2087625088.SGD","LU0289739343.SGD","LU2272731865.HKD","LU0345768153.USD","LU1642822529.SGD","LU1868837136.USD","IE00B19Z9505.USD","LU2954938101.SGD","TSLY","IE000M9KFDE8.USD","LU1400636491.USD","BK4551","TSLS","BK4605","AMDW","LU0724617625.USD","LU1261432733.SGD","SG9999013486.USD","LU1880398554.USD","BK4230","IE00BGHQDM52.EUR","LU0820561818.USD","LU1267930730.SGD","BMNG","AAL","LU0820561909.HKD","LU1861559042.SGD","LU0053666078.USD","SG9999015986.USD","IE00BHPRN162.USD","CRSH","LU1868837300.USD","IE00B7KXQ091.USD","CRML","IE000ITXATA3.USD","LU1815333072.USD","LU1923622614.USD","BK4575","IE0002270589.USD","AMDG","IE0009G5SDU7.USD","SG9999001424.SGD","LU1037948897.HKD","IE000KEQY171.SGD","BK4515","LU0225283273.USD","LU0289961442.SGD","LU0823411888.USD","LU0861579265.USD","LU0353189763.USD","LU0823421333.USD","LU1791710400.SGD","IE00BDRTCR15.USD","LU2458330243.SGD","LU0957791311.USD","LU2028103732.USD","IE00BMPRXR70.SGD","LU1989772840.SGD","TSDD","LU0354030511.USD","LU0820562030.AUD","LU2999663052.SGD","LU0390134368.USD","MULL","NVD","SG9999014880.SGD","LU0323591593.USD","LU0109392836.USD","IE00B7SZLL34.SGD","LU2249611893.SGD","TSLR","SG9999015952.SGD","LU0097036916.USD","LU0472753341.HKD","BK4612","LU1992135472.HKD","LU2242650005.HKD","NVDS","LU0154236417.USD","LU1548497426.USD","SGMT","LU0094547139.USD","IE0034235295.USD","LU1791710582.SGD","LU0345769631.USD","LU2092627202.USD","NVDA","SGXZ31699556.SGD","PLTD","IE0034235303.USD","LU2125909247.SGD","LU2430703178.SGD","LU2413666699.HKD","TSLL","BK4500","IE00B1BXHZ80.USD","LU0787776722.HKD","BK4581","LU2433249047.HKD","LINT","BK4022","LU2592432038.USD","LU2756315664.SGD","AMZN","LU2089283258.USD","LU2125154935.USD","LU0786609619.USD","LU2098885051.SGD","SG9999014906.USD","LU2360032135.SGD","QCMD","LU2361044865.SGD","NVDG","LU2237957902.USD","MU","LU0792757196.USD","LU0265550946.USD","IE0004445239.USD","TSLA","SG9999002604.SGD","LU0143551892.USD","SGXZ58947870.SGD","LU1880398471.USD","LU2023250330.USD","LU0683600562.USD","AMDL","IE00BKPKM429.USD","SOFI","IE0001KFT4U8.USD","LU2108987350.USD","2NVD.UK","LU1035775433.USD","LU2505996681.GBP","LU2357125470.USD","LU0056508442.USD","SG9999014559.SGD","LU0096364046.USD","LU1951198990.SGD","MUU","LU1823568750.SGD","LU0061475181.USD","SG9999014914.USD","LU0347712357.USD","LU1815336760.USD","IE0009356076.USD","LU2191332357.HKD","LU1989772923.USD","LU0889565833.HKD","LU0310800379.SGD","LU0719512351.SGD","LU1861127337.USD","NVDU","IE00BVYPNQ40.USD","LU2487616109.SGD","BK4592","LU2294711713.HKD","LU2552382215.SGD","BK4549","LU1935042215.USD","SG9999004303.SGD","LU2247934214.USD","LU2168563687.JPY","BK4511","LU2462591350.SGD","BK4574","LU0964807845.USD","LU0256863902.USD","LU2168564495.EUR","LU2552382058.USD","TSYY","LU0170899867.USD","SNVD.UK","LU1366333091.USD","NVIW.SI","LU2089985449.USD","AALG","BK4566","BK4598","LU1066051225.USD","LU0006306889.USD","BK4512","LU0061474960.USD","LU1400636574.HKD","LU2125910500.SGD","BK4535","BK4008","LU0511384066.AUD","BMNR","IE00BDCRKT87.USD","LU2168564222.USD","TSLQ","LU1691799644.USD","LU2458330169.SGD","LU0942090050.USD","LU1119994496.HKD","LU1983260115.SGD","SG9999014567.USD","LU1551013342.USD","LU0868494617.USD","LU1718418525.SGD","LU0203201768.USD","LU0321505868.SGD","TEST","LU2286300806.USD","LU2746668461.USD","SG9999015341.SGD","IE00BQXX3C00.GBP","LU0528227936.USD","BK4567","SG9999013478.USD","NVDB","LU1244550577.SGD","LU2065171402.SGD","LU1935043536.SGD","HK0000532082.HKD","LU1571399168.USD","LU0072462426.USD","TSLZ","LU1267930813.SGD","SG9999014542.SGD","LU1242518857.USD","LU1803068979.SGD","HK0000304797.USD","LU1839511570.USD","LU2506951792.HKD","NVDW","LU1934455194.USD","IE0034235188.USD","LU0158827781.USD","IE00BFSS7M15.SGD","LU0203345920.USD","BK4550","LU2491049909.HKD","07766","TSLP","LU1989764748.USD","LU0823414478.USD","LU2430703251.USD","LU0441851309.USD","AAPL","TLA","LU2125909916.SGD","LU2148611432.USD","LU1551013425.SGD","LU1712237335.SGD","GB00BDT5M118.USD","IE00BJLML261.HKD","LU0320765059.SGD","HK0000914686.HKD","LU2045819591.USD","LU2491050071.SGD","LU1914381329.SGD","PLTR","IE00BKDWB100.SGD","LU0265550359.USD","LU1066051811.HKD","LU0203202063.USD","LU2456880835.USD","LU1804176565.USD","SG9999015358.SGD","LU1935042991.SGD","LU1988902786.USD","LU0444971666.USD","LU1674673691.USD","LU2213496289.HKD","LU2471134796.USD","LU1974910355.USD","LU1435385759.SGD","BK4547","LU0215105999.USD","LU2322448957.HKD","LU0210528500.USD","LU1674673428.USD","SG9999002414.USD","LU0868494708.USD","IE00B19Z3581.USD","LU0689472784.USD","LU0061474705.USD","LU1868836591.USD","LU1623119135.USD","LU0127658192.USD","LU2355687059.USD","IE00B19Z8W00.USD","IE00BSNM7G36.USD","LU1989764664.SGD","TSLW","IE00BQXX3D17.EUR","IE00B5949003.HKD","LU0077335932.USD","LU2089284900.SGD","INTC","IE00BYXW3230.USD","LU2063271972.USD","AMDU","LU0345770993.USD","LU1037948541.HKD","LU2896262040.SGD","BK4543","LU2065170008.USD","SG9999015945.SGD","LU2083900584.USD","LU0057025933.USD","LU2491050154.USD","IE00BJTD4N35.SGD","SG9999002232.USD","SGXZ81514606.USD","LU2361045086.USD","IE00BMPRXQ63.HKD","MUD","LU1267930490.SGD","LU1699723380.USD","LU2272731782.SGD","TQQQ","LU2242649171.HKD","LU2461242641.AUD","NDX","BK4122","BK4533","IE00BJJMRY28.SGD","LU0266013472.USD","LU2168564065.EUR","LU2237957811.SGD","SG9999006266.SGD","LU1814569148.SGD","LU2054465674.USD","LU1633808545.USD","LU2471134952.CNY","LU0476273544.USD","LU1046421795.USD","LU0316494557.USD","LU0823414551.USD","BK4548","LU2250418816.HKD","BK4529","BK4554","LU2065169927.USD","SG9999002406.SGD","NVDY","SG9999001135.SGD","LU1066053197.SGD","IE00B1XK9C88.USD","IE00BJTD4V19.USD","LU2236285917.USD","LU0289960550.SGD","LU2326559502.SGD","LU1670756490.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630113053","title":"Top Midday Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2630113053","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630113053?lang=en_us&edition=fundamental","pubTime":"2026-04-28 02:01","pubTimestamp":1777312877,"startTime":"0","endTime":"0","summary":"Sagimet Biosciences (SGMT) said Monday it has priced an underwritten offering of about 29.2 million shares at $6.00 each to raise about $175 million to help fund its clinical trial.Shares soared 43% a","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MANE","BK4139","BK4007","ORKA","SGMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630031131","title":"Why Is Sagimet Biosciences Stock Trading Higher On Monday?","url":"https://stock-news.laohu8.com/highlight/detail?id=2630031131","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630031131?lang=en_us&edition=fundamental","pubTime":"2026-04-28 01:48","pubTimestamp":1777312080,"startTime":"0","endTime":"0","summary":"Sagimet shares surge as Phase 3 acne trial plans and $175M offering fund pipeline through 2028, with technicals showing strong momentum.","market":"hk","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/04/27/Healthcare-Funding-Pressure.jpeg?optimize=medium&dpr=2&auto=webp&width=260","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/04/27/Healthcare-Funding-Pressure.jpeg?optimize=medium&dpr=2&auto=webp&width=260"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/trading-ideas/movers/26/04/52073823/why-is-sagimet-biosciences-stock-trading-higher-on-monday","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/trading-ideas/movers/26/04/52073823/why-is-sagimet-biosciences-stock-trading-higher-on-monday","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["BK4150","SGMT","BK4217","BK4139","SMA","RSI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630456396","title":"Sagimet Biosciences Shares Rise With Focus on Acne Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2630456396","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630456396?lang=en_us&edition=fundamental","pubTime":"2026-04-27 20:02","pubTimestamp":1777291320,"startTime":"0","endTime":"0","summary":"Sagimet Biosciences shares rose after the company said it would focus on advancing development of its acne treatment in the U.S.The stock climbed 29% to $7.55 in premarket trading Monday. Through Friday's close, the stock had ticked down 1% this year.The clinical-stage biopharmaceutical company said it plans to start a U.S. Phase 3 trial of denifanstat, a treatment for moderate to severe acne, in the second half of this year.The decision marks a broader strategic shift to prioritize Sagimet's dermatology business while pursuing nondilutive funding options for its program in the liver disease MASH, or metabolic dysfunction-associated steatohepatitis, Chief Financial Officer Thierry Chauche said.Sagimet had also been developing a combination of denifanstat and resmetirom to treat MASH. The company reported the completion of a Phase 1 trial in December 2025, and expects the combination treatment to be ready for a Phase 2 trial in the second half of this year.In January, Sagimet's license ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","01672","SGMT","BK1161","BK1574","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630951923","title":"Sagimet Highlights Pipeline Progress and Strategic Corporate Developments","url":"https://stock-news.laohu8.com/highlight/detail?id=2630951923","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630951923?lang=en_us&edition=fundamental","pubTime":"2026-04-27 19:37","pubTimestamp":1777289877,"startTime":"0","endTime":"0","summary":"The latest update is out from Sagimet Biosciences, Inc. Class A ( ($SGMT) ). On April 27, 2026, Sagimet updated its investor slide presentation and...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/sagimet-highlights-pipeline-progress-and-strategic-corporate-developments?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/sagimet-highlights-pipeline-progress-and-strategic-corporate-developments?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4097","PRGS","LU2065732104.USD","BK4139","SGMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630039318","title":"Sagimet Biosciences Inc - Prices 29.2 Mln Series a Common Shares at $6.00 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2630039318","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630039318?lang=en_us&edition=fundamental","pubTime":"2026-04-27 19:15","pubTimestamp":1777288504,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260427:nTUA3LNMZ5:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SGMT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630482393","title":"Sagimet Biosciences Announces Pricing of $175.0 Million Underwritten Offering of Series A Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2630482393","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630482393?lang=en_us&edition=fundamental","pubTime":"2026-04-27 19:15","pubTimestamp":1777288500,"startTime":"0","endTime":"0","summary":"SAN MATEO, Calif., April  27, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabol","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/27/3281497/0/en/Sagimet-Biosciences-Announces-Pricing-of-175-0-Million-Underwritten-Offering-of-Series-A-Common-Stock.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["USA","BK4139","SGMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630393830","title":"Sagimet plans US Phase 3 denifanstat acne trial start in H2 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2630393830","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630393830?lang=en_us&edition=fundamental","pubTime":"2026-04-27 19:06","pubTimestamp":1777287982,"startTime":"0","endTime":"0","summary":"Sagimet shifted capital focus to dermatology, planning a US Phase 3 trial of once-daily oral denifanstat in moderate to severe acne in 2H 2026, subject to IND clearance.Positive topline results were already reported from an open-label Phase 3 long-term safety study of denifanstat in China, showing it was generally well tolerated and supported improvements across measured efficacy outcomes.Development of FASN inhibitor TVB-3567 continued in a first-in-human Phase 1 trial, with Phase 2 in acne targeted for 2H 2026.MASH program for denifanstat plus resmetirom was positioned as Phase 2-ready in 2H 2026, with further clinical work deferred until non-dilutive funding is secured.Sagimet scheduled a KOL webcast for April 30, 2026 to outline its acne development strategy for denifanstat.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260427:nNDL6cVw3k:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","BK4139","BK4588","IE00B3QW5Z07.USD","LU2095319765.USD","LU0314104364.USD","SGMT","IE00BN0W2W23.USD","LU2210150020.SGD","SG9999014013.SGD","SG9999014021.USD","SG9999014005.SGD","SG9999014039.USD","BK4112","IE00B64PRP62.GBP","BK4585","LU2210149790.SGD","IE00BN0W2T93.GBP","IE00BGHQF748.EUR","NDAQ","IE00BN0W2V16.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630989453","title":"Sagimet Biosciences Inc - Plans Phase 3 Trial of Denifanstat in U.S. Acne Patients in H2 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2630989453","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630989453?lang=en_us&edition=fundamental","pubTime":"2026-04-27 19:00","pubTimestamp":1777287603,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260427:nTUA6XFJTY:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SGMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630393354","title":"Sagimet Biosciences Provides Strategic and Corporate Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2630393354","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630393354?lang=en_us&edition=fundamental","pubTime":"2026-04-27 19:00","pubTimestamp":1777287600,"startTime":"0","endTime":"0","summary":"Phase 3 clinical trial of denifanstat in moderate to severe acne patients for the U.S.planned to initiate in second half of 2026 First-in-human Phase 1 clinical trial of FASN inhibitor TVB-3567 ongoin","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/27/3281481/0/en/Sagimet-Biosciences-Provides-Strategic-and-Corporate-Updates.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00511","BK4139","IND","BK1145","SGMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629841050","title":"Sagimet Biosciences announces annual shareholder meeting notice","url":"https://stock-news.laohu8.com/highlight/detail?id=2629841050","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629841050?lang=en_us&edition=fundamental","pubTime":"2026-04-22 04:13","pubTimestamp":1776802401,"startTime":"0","endTime":"0","summary":"Sagimet Biosciences schedules virtual annual stockholder meeting for June 12, 2026.Shareholders will vote on election of four Class III directors for terms expiring in 2029.Ballot also includes ratification of KPMG as independent registered public accounting firm for fiscal 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sagimet Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 21, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260421:nNDL5gFpbC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SGMT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.sagimet.com","stockEarnings":[{"period":"1week","weight":0.2986},{"period":"1month","weight":0.4523},{"period":"3month","weight":0.3422},{"period":"6month","weight":-0.1068},{"period":"1year","weight":0.9364},{"period":"ytd","weight":0.2855}],"compareEarnings":[{"period":"1week","weight":0.0094},{"period":"1month","weight":0.0998},{"period":"3month","weight":0.0414},{"period":"6month","weight":0.0566},{"period":"1year","weight":0.2904},{"period":"ytd","weight":0.0568}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.","exchange":"NASDAQ","name":"Sagimet Biosciences Inc.","nameEN":"Sagimet Biosciences Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Sagimet Biosciences Inc.(SGMT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Sagimet Biosciences Inc.(SGMT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Sagimet Biosciences Inc.,SGMT,Sagimet Biosciences Inc.股票,Sagimet Biosciences Inc.股票老虎,Sagimet Biosciences Inc.股票老虎国际,Sagimet Biosciences Inc.行情,Sagimet Biosciences Inc.股票行情,Sagimet Biosciences Inc.股价,Sagimet Biosciences Inc.股市,Sagimet Biosciences Inc.股票价格,Sagimet Biosciences Inc.股票交易,Sagimet Biosciences Inc.股票购买,Sagimet Biosciences Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Sagimet Biosciences Inc.(SGMT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Sagimet Biosciences Inc.(SGMT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}